Among active 13F managers last quarter, 6 opened and 5 added, while 8 reduced; the largest holder to move was Janus Henderson Group Ltd. (−28%). Over the last 180 days, 1 insider bought and 3 insiders sold, a net +$509K in open-market trades.
Funds lean in and no leg opposes.
44 tracked 13F filers disclose a position in NBP as of the latest SEC 13F filings, a combined $55.0M in reported value. Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
| # | Fund | Shares | Position value | Last move | As of | History |
|---|---|---|---|---|---|---|
| 1 | Janus Henderson Group Ltd. | 6.0M | $14.8M | ▼−28% Reduced · −2.4M sh | Q1 2026 | |
| 2 | HHLR Advisors, LTD. | 6.0M | $11.7M | —Held | Q2 2026 | |
| 3 | Morgan Stanley | 3.8M | $9.4M | ▲+1.4% Added · +53K sh | Q1 2026 | |
| 4 | Siren, L.L.C. | 2.0M | $3.9M | ▼−33% Reduced · −995K sh | Q2 2026 | |
| 5 | Candriam S.C.A. | 1.1M | $2.2M | —Held | Q2 2026 | |
| 6 | Adage Capital Partners GP, L.L.C. | 1.0M | $2.5M | —Held | Q1 2026 | |
| 7 | BlackRock, Inc. | 686K | $1.3M | ▲+9.3% Added · +59K sh | Q2 2026 | |
| 8 | Citadel Advisors LLC | 623K | $1.2M | ▲+274% Added · +456K sh | Q2 2026 | |
| 9 | E Fund Management Co., Ltd. | 589K | $1.1M | ▲New +589K sh | Q2 2026 | |
| 10 | Exome Asset Management LLC | 577K | $1.1M | —Held | Q2 2026 | |
| 11 | State Street Corp | 360K | $703K | ▼−2.6% Reduced · −10K sh | Q2 2026 | |
| 12 | Woodline Partners LP | 350K | $683K | ▼−50% Reduced · −350K sh | Q2 2026 | |
| 13 | Fiera Capital Corp | 316K | $616K | —Held | Q2 2026 | |
| 14 | Barclays PLC | 299K | $736K | ▼−52% Reduced · −330K sh | Q1 2026 | |
| 15 | Renaissance Technologies LLC | 272K | $670K | ▲New +272K sh | Q1 2026 | |
| 16 | Dimensional Fund Advisors LP | 146K | $360K | ▼−1.4% Reduced · −2K sh | Q1 2026 | |
| 17 | ALPS Advisors Inc | 117K | $228K | ▲Added Added · +117K sh | Q2 2026 | |
| 18 | Goldman Sachs Group Inc | 112K | $277K | ▼−20% Reduced · −28K sh | Q1 2026 | |
| 19 | XTX Topco Ltd | 102K | $250K | ▼−28% Reduced · −39K sh | Q1 2026 | |
| 20 | Leonteq Securities AG | 80K | $197K | ▲+281% Added · +59K sh | Q1 2026 | |
| 21 | BNP Paribas Financial Markets | 73K | $180K | ▼−37% Reduced · −44K sh | Q1 2026 | |
| 22 | Geode Capital Management, LLC | 69K | $134K | —Held | Q2 2026 | |
| 23 | UBS Group AG | 64K | $156K | ▼−65% Reduced · −118K sh | Q1 2026 | |
| 24 | JPMorgan Chase & Co | 57K | $129K | ▼−56% Reduced · −74K sh | Q1 2026 | |
| 25 | Caitong International Asset Management Co., Ltd | 30K | $59K | ▲+17% Added · +4K sh | Q2 2026 |
Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
Last quarter, 6 funds opened a new position in NBP and 5 added to an existing one, while 8 reduced. Based on 13F filings from active, signal-eligible managers (passive index funds and other mechanical holders are excluded from this count).
| Company | Co-held by | Their position there |
|---|---|---|
| Alphabet Inc-CL AGOOGL | 23 funds | $10.6B |
| Nvidia CorpNVDA | 22 funds | $31.1B |
| Microsoft CorpMSFT | 22 funds | $20.1B |
| Eli Lilly & CoLLY | 22 funds | $8.1B |
| Lam Research CorpLRCX | 22 funds | $4.8B |
| Visa Inc-Class A SharesV | 22 funds | $3.7B |
| Intel CorpINTC | 22 funds | $2.6B |
| General ElectricGE | 22 funds | $2.1B |
| Boston Scientific CorpBSX | 22 funds | $2.0B |
| Texas Instruments IncTXN | 22 funds | $2.0B |
| Uber Technologies IncUBER | 22 funds | $1.1B |
| Amazon.com IncAMZN | 21 funds | $16.8B |
Ranked by how many of NBP's tracked holders also hold each name. The last column is those co-holders' combined reported position in that name, not in NBP.
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| Aug 31, 2026 | Xu Cong Claire | EVP, Clinical Development | Sell (S) | 3K | $3K |
| Jul 6, 2026 | Xu Cong Claire | SVP, Clinical Development | Sell (S) | 4K | $4K |
| Jun 18, 2026 | Dennis Phillip Andrew | Chief Medical Officer | Sell (S) | 8K | $6K |
| Jun 1, 2026 | Xu Cong Claire | SVP, Clinical Development | Sell (S) | 3K | $14K |
| May 14, 2026 | Cao Sean Wuxiong | See Remarks, Director | Sell (S) | 21K | $43K |
| Apr 24, 2026 | Hagler Mark Arnold | See Remarks | Buy (P) | 230K | $577K |
Where institutional funds (13F), corporate insiders (Form 4) and US House members (STOCK Act) are buying or selling the same name in the same window. Green is buying, red is selling.
Insiders and Congress: last 180 days. Funds: latest 13F, top 100 holders incl. passive
| Source | Buying | Selling | Net |
|---|---|---|---|
13F funds Top 100 holders by value, passive included; the hero counts active managers only | 10 | 18 | – |
Insiders Form 4 open-market | 1 | 3 | +$509K |
US House STOCK Act trades | 0 | 0 | $0 |
Capital Rotation reports where institutional capital disclosed rotating, as of the latest public SEC 13F filings. It is data, not investment advice, a recommendation, or a prediction. Filings lag about 45 days and cover long US equity positions only. Past disclosed flows do not indicate future prices. Do your own research; consult a licensed advisor.
Connected entities for NBP
This stock page is the public Follow view. For one current, evidence-backed answer, use capital_change_brief through REST or MCP. It compares tracked 13F changes with qualifying Form 4 activity and cites the SEC evidence.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/stocks/NBP/capital-change-brief"
Use Arkolith's capital_change_brief for NBP. Tell me what changed, whether insider activity corroborates it, and cite the SEC evidence.
13F holdings + Form 4 insider transactions + end-of-day price history + the live filing stream, joined for NBP. Filings are public domain, sourced to SEC EDGAR; price series derived from end-of-day closes.